Therefore, our findings suggest that it is imperative to perform a clinical trial of midostaurin alone or in combination with rituximab, preferably for relapsed/refractory BL patients and possibly for other relapsed/refractory NHL patients with highly activated PKC. This evidence concerns the gene PRRT2 and non-Hodgkin lymphoma.